Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Allergan Industrie, SAS is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This level of activity suggests a targeted approach to patent prosecution for the company's pharmaceutical interests, focusing on a small number of key innovations.
The portfolio's active matters are distributed across a matching number of distinct examiners and 2 distinct art units. This distribution indicates that each pending case is being evaluated independently by different specialists within the Biotechnology & Pharmaceuticals field, requiring the company to maintain consistent technical arguments across different administrative sections.
PALLAY, MICHAEL B is identified as the busiest examiner, currently handling 1 pending office action. Since there are a total of two active matters, the workload is split among the distinct examiners, requiring the company to address different sets of examiner expectations simultaneously. Success depends on meeting the specific requirements of the 1 pending office action under this examiner while managing the other active filing.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALLAY, MICHAEL B | 1 | 55.9% | +33.6% |
| PATEL, AREN | 1 | 77.6% | +17.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18926155 | HEAT STABLE HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE | PALLAY, MICHAEL B | — |
| 18544017 | THREAD INSERTION DEVICES | PATEL, AREN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18926155 | HEAT STABLE HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE | PALLAY, MICHAEL B | — |
| 18544017 | THREAD INSERTION DEVICES | PATEL, AREN | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 3774 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18926155 | HEAT STABLE HYALURONIC ACID COMPOSITIONS FOR DERMATOLOGICAL USE | PALLAY, MICHAEL B | 1617 | §101DP | Non-Final OA | — | Pending | Oct 24, 2024 |
| 18544017 | THREAD INSERTION DEVICES | PATEL, AREN | 3774 | §102§103 | Non-Final OA | — | Pending | Dec 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAllergan Industrie, SAS has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Michael B Pallay has the most, with 1 of Allergan Industrie, SAS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.